Select Page
MobiHealth News reports on success of HealthPROMISE Digital Medicine Solution

MobiHealth News reports on success of HealthPROMISE Digital Medicine Solution

On Nov. 13, MobiHealth News reported on the results of a two-year clinical trial for HealthPROMISE. HealthPROMISE, an app-based platform developed at Mount Sinai, is designed to improve the quality of care for patients who are struggling with inflammatory bowel disease (IBD). The MobiHealth News publication was based on clinical data recently presented at the Advances in Inflammatory Bowel Diseases Conference.

HealthPROMISE is a unique, cloud-based patient reported outcome (PRO) and decision support tool that empowers patients and providers: patients track their quality of life and symptoms, while providers can use the visual data in real time through EHR integration to provide better care to the entire patient population. During the trial, researchers focused on changes in the quality of care metrics between the groups, while observing shifts in quality of life scores, discovering the proportion of patients who reported controlled disease status in each group and documenting any decreases in IBD related emergency visits and hospitalizations.

According to Dr. Ashish Atreja, HealthPROMISE improved patient health outcomes and long-term engagement by implementing tools that allow care teams to monitor symptoms and more conveniently communicate with their patients. The platform assists with the collection of symptom and adherence data, which can then be reviewed while designing care strategies. Patients using HealthPROMISE are able to update their medical information while receiving a summary of quality care metrics and quality of life trends specific to IBD.

“Patients were coming to see us once or twice a year, but a lot of times we were finding patients falling through the cracks [and] there were symptoms they had for many months before they came back to us,” Atreja said to MobiHealth News. “Three or four hours of physician-time a year is not relevant for many of the patients. We need to have a way to proactively assess how they’re doing every single week or every single month.”

HealthPROMISE was tested during a two-year trial sponsored by the National Institutes of Health. During the trial, 320 patients with IBD were prescribed with app-based digital technologies to aid in their care. The patients were randomly placed into two groups: one group of 158 patients was assigned a basic medical education app, while a second group of 162 patients was provided with HealthPROMISE.

After 575 days, it was found that the 320 patients had significant improvement in IBD specific quality of life measures. However, patients prescribed with HealthPROMISE were found to have reported a significantly higher quality of life. Uncontrolled anxiety and fatigue were the primary factors when participants reported poor quality of life. Furthermore, app usage data showed that about 75 percent of HealthPROMISE users continued to log in and update PROs throughout the duration of the study.

According to Dr. Atreja, patients who used HealthPROMISE felt they had an ongoing relationship with their physician, even outside of the clinical setting. Dr. Atreja said that continued contact between patients and their care teams was a factor for continued engagement with HealthPROMISE, resulting in patients using the platform regularly.

Rx.Health’s RxUniverse Recognized Among Top 15 Medical Solutions of 2017 by MEDICA Jury Panel

Rx.Health’s RxUniverse Recognized Among Top 15 Medical Solutions of 2017 by MEDICA Jury Panel

Rx.Health’s RxUniverse was selected as one of the top 15 app-based medical solutions worldwide in advance of the 2017 MEDICA App Competition, which is recognized as the world’s leading trade fair for the medical industry. In order to be considered, apps must be novel, solve a large and unmet need, be scalable internationally, and pass the scrutiny of the conference’s jury panel. This year’s panel was comprised of nearly a dozen leading healthcare leaders and innovators from around the globe.

On Nov. 15, Rx.Health CEO Ed Berde will travel to Dusseldorf, Germany to present at the conference and meet with leaders from health systems, payers and the pharmaceutical industry interested in promoting innovation through RxUniverse’s unique platform approach, which can integrate multiple solutions under one workflow.

“This is further validation for RxUniverse and how it can harness the power of tremendous innovation happening worldwide and transform care by integrating and delivering those solutions to the hands of patients at right time to deliver the right outcomes,” Berde said “Our selection at MEDICA speaks to a global appeal for this platform and we will be looking to further expand on our meaningful partnerships with key international players.”

Click here for the full press release.

RxUniverse’s Pilot Study Results to be Presented at AMIA 2017 Annual Symposium

RxUniverse’s Pilot Study Results to be Presented at AMIA 2017 Annual Symposium

Rx.Health is proud to support the 2017 Annual American Informatics Association Conference in Washington, D.C. During the conference, which is held from Nov. 4 through Nov. 8, Dr. Ashish Atreja will be presenting the results of the RxUniverse pilot study that was conducted at the Mount Sinai Health System.

“AMIA assembles the perfect audience to present the pilot study of RxUniverse, so this presentation should be incredibly exciting,” Dr. Atreja said. “Attendees understand that informatics are a crucial and necessary component of advancing healthcare to a patient-centric methodology. Digital Medicine is at the forefront of this progression, and we now have the statistics and evidence to support that statement.”

RxUniverse’s six-week pilot study was conducted with the goal of prescribing 100 mobile health apps to patients. Exceeding test result expectancies by more than 200 percent, the pilot study involved 40 clinicians and health care providers at five clinical sites at Mount Sinai. Clinicians prescribed over 2,000 mobile health apps during the trial period, and RxUniverse received an 84.2 score on the System Usability Scale. SUS is used to evaluate technology products and compare them to industry standards of usability and learnability.

This SUS score places RxUniverse in the top 96 percentile of technology products. The statistics resulting from the RxUniverse pilot study provides further evidence that a platform approach to engaging patients using Digital Medicine is a valuable tool in bridging the gap between innovation in health care and patient engagement.

AMIA actively supports research and practice in healthcare informatics and offers a platform for professionals, students and patients to come together and discuss the future of informatics in healthcare. Over the last 35 years, informatics have grown exponentially to improve health, and are key to accelerating the current goals of healthcare reform.

To learn more, view the press release here.

Dr. Atreja to Present the Power of Platform-Based Digital Medicine at CHIME CIO Forum

Dr. Atreja to Present the Power of Platform-Based Digital Medicine at CHIME CIO Forum

Digital Medicine has significant potential to enable transformation in value-based care. However, health systems have struggled to adopt the technology necessary to integrate Digital Medicine solutions into their clinical workflow while complying with FDA guidelines and regulations.

On Thursday, Nov. 2, Rx. Health Cofounder Dr. Ashish Atreja, who is also the Chief Innovation and Engagement Officer of Medicine at the Mount Sinai Health System, will present on the opportunity that Digital Medicine is bringing to health care providers at the CHIME CIO Forum in San Antonio. Dr. Atreja’s presentation will touch on the substantial impact Digital Medicine could have on health systems by creating better care for patients that in turn promotes value-based care transformation in treatment.

“For me, what’s so exciting about CHIME is that CIOs have a forum for discussions around effectively implementing digital technologies in their health systems, which is an area that I’ve been involved in for more than a decade” Dr. Atreja said. “Recent studies have shown that an effective way to implement these solutions is through a platform-based system, which will be increasingly recognized as a necessary tool in any sophisticated practice.”

Dr. Atreja’s presentation will identify challenges faced in adopting Digital Medicine, such as FDA guidance and related regulations for mhealth apps, telemedicine and other digital health technologies. The discussion will focus on how a platform-based approach can simplify clinical workflow and help onboard Digital Medicine across all specialties within a health system.

Dr. Atreja will share how work done at Mount Sinai can be readily applied to other health systems. Yale New Haven Health has become first health system in Connecticut to use a similar approach to digital medicine prescribing to fulfill their value-based healthcare needs. The discussion will also delve into other topics that are crucial to the nation’s leading health systems’ CIOs, such as MACRA compliance and population health management for underserved communities.

The 2017 CHIME Fall CIO Forum provides an opportunity for thought leaders and industry luminaries to discuss any and everything about healthcare IT. Featured discussions in this year’s program encompass a wide variety of topics, including a deeper focus on patient identification, cybersecurity, data analytics, clinical workflow, public policy and cutting-edge innovation that’s transforming health care.

For more information on the event, see CHIME’s website for a full listing of presenters and topics. For those in attendance, be sure to catch Dr. Atreja’s presentation on Nov. 2.

Rx.Health Leadership Presents Data on CHF Readmission at Connected Health Conference

Rx.Health Leadership Presents Data on CHF Readmission at Connected Health Conference

On Oct. 25, leading innovators in healthcare will convene in Boston to attend the ninth annual Connected Health Conference. Widely considered one of the premier events in healthcare, this year’s conference will host over 2,000 attendees focused on changing the way the Country thinks about health and wellness. The Rx.Health team will be in Boston to engage, exhibit and speak throughout the 3-day conference.

“Every year we look forward to attending Connected Health, but after looking back at the success stories with our academic partners in 2017, we’re really excited to engage with other pioneers in healthcare,” said Rx.Health Cofounder and CEO, Ed Berde. “Health systems, payers and industry that wants to learn how to leverage a singular platform for innovation and clinical transformation should stop by Kiosk 101 at the Startup Pavilion to talk to my team. Our academic partners will be presenting on how Digital Prescribing platform has helped with readmission reduction, quality improvement (supporting MIPS) as well as patient-centered decision aids in different specialties ranging from cardiology to GI to cancer care.”

In an effort to collaborate with as many attendees as possible during the conference, the majority of Rx.Health’s core leadership team will be in attendance. Berde will be joined by Pavan Choksi, the VP of Corporate Development, and Mark Cittadino who heads Sales & Growth.

Scientific cofounder Dr. Ashish Atreja will also be in Boston for the event as a featured speaker. In addition to his Oct. 25 panel discussion centered on fueling the innovation economy in connected health industry, Dr. Atreja will also present on the final day of the conference to discuss protocols of a digital health pilot study. Using RxUniverse’s pilot at Mount Sinai Health System as a model, Dr. Atreja will touch on the implications and takeaways surrounding the success of that study, which surpassed its expected outcome by 200 percent. More details on that study are available at http://Rx.Health.

Dr. Atreja will also be presenting the results of a study conducted at Mount Sinai in which 60 patients with Chronic Heart Failure were asked to use two mobile apps to track blood pressure and weight. The study found that patients monitoring their condition with Digital Medicine were significantly less likely to be readmitted to the hospital within the first 30 days after a procedure. Among the 60 patients, the readmission rate during the study was just 10 percent, compared to Mount Sinai’s average of 22.8 percent and the national average of 25 percent. After the study concluded, 70 percent of participants continued to use Digital Medicine to track their blood pressure and weight.

CHC17 offers a unique opportunity to interact with a diverse audience of attendees, from members of academia to the investment community. The conference offers perhaps the clearest view of healthcare through the prism of innovation, highlighting trends and market dynamics captivating the industry.

Stop by Kiosk 101 in the startup pavilion to speak with our team, and be sure to catch Dr. Atreja’s talks on October 25 and 27.